Vanoglipel

N/A

Report date: 2025/11/10 15:23:40
NME

Base Information

Drug NameVanoglipel
Drug Alias NameDA-1241
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlucose-dependent insulinotropic receptor agonists
TargetsGlucose-dependent insulinotropic receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Metabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesDong-A Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNeurobo Pharmaceuticals Inc
Inactive CompaniesDong-A ST Co Ltd
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A